Allecra is a clinical-stage biopharmaceutical company that is committed to combating antibiotic resistance. Founded in 2013, the company is developing novel therapies to overcome emergent resistance mechanisms and address the urgent need for safe and effective alternatives to combat antibiotic-resistant infections. Their lead product candidate, cefepime/enmetazobactam, has demonstrated superiority over standard care in patients with complicated urinary tract infections (cUTIs) in a Phase 3 trial.

Based on these promising results, Allecra is preparing submissions for marketing approval in the U. S. With significant patent protection covering their proprietary enmetazobactam, Allecra is at the forefront of tackling the global antibiotic resistance crisis.

Recognizing the increasing prevalence of Extended-Spectrum β-lactam resistant pathogens (ESBLs) and the limitations of current antibiotics, Allecra is developing cefepime/enmetazobactam to address these critical resistance issues. By actively seeking partnerships, Allecra aims to strengthen their antibiotic pipeline and contribute to public health preparedness, especially in the face of challenges like COVID-19. With their dedicated team and commitment to innovation, Allecra is poised to make a significant impact in the field of antibiotic therapeutics